
Stocks Higher as In...


| Price and Volume | |
|---|---|
| Recent Price | 1.79 |
| 52 Week High | 4.95 |
| 52 Week Low | 1.08 |
| Avg. Daily Vol. (Mil) | 1.65 |
| Beta (3 year) | 2.28 |
| Share Related Items | |
| Mkt Cap (Mil) | 95.13 |
| Shares Out (Mil) | 53.15 |
| Float (Mil) | 45.12 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.90 |
| Current Ratio | 3.10 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 5.40 |
| Price/Book | 0.00 |
| Price/Cash Flow | -2.20 |
| Per Share Data | |
| Earnings | -0.75 |
| Sales | 0.33 |
| Book Value | 0.00 |
| Cash Flow | -0.80 |
| Business Summary | |
|---|---|
| BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. | |
| General Information | |
| 4505 Emperor Boulevard
Suite 200 Durham, NC 27703 |
|
| www.biocryst.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 40 | |
| CEO: Jon P. Stonehouse | |
| Short Interest | |
| Current Month (Mil) | 6.84 |
| Previous Month (Mil) | 7.38 |
| Short Interest Ratio (Days) | 5.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -92.90 |
| Return on Investments | -160.00 |
| Profitability | |
| Gross Margin | 99.30 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |